Regeneron Earnings Obliterate Views; Biotech Giant Tops Buy Point

 Regeneron stock rose on Thursday after the biotech company reported adjusted income of $25.80 per share on $5.14 billion in second-quarter sales.

On average, analysts polled by FactSet expected Regeneron Pharmaceuticals (REGN) to earn $17.94 per share on $3.96 billion in sales.

In the year-earlier period, Regeneron earnings were $7.16 per share on $1.95 billion in sales.

For the year, Regeneron gave some positive forecasts, but no specifics on earnings or sales. Analysts called for adjusted profit of $49.46 a share and $12.24 billion in sales.

https://www.investors.com/news/technology/regeneron-stock-regeneron-earnings-q2-2021/